SOURCE: Active Biotech

February 13, 2006 05:11 ET

Invitation Teleconference - Active Biotech AB

Thursday 16 February, 14:00 CET.

LUND, SWEDEN -- (MARKET WIRE) -- February 13, 2006 --

Active Biotech's President & CEO Sven Andréasson and CFO Hans Kolam will present and comment on the Year End report January-December, 2005.

To listen and to view the presentation: please visit

To participate in the teleconference, please call +44 (0) 20 7162 0125 (UK).

To listen to the conference and/or to view the presentation afterwards, please call +44 (0) 20 7031 4064 (UK), access code 691235 or visit

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA.

Active Biotech AB
Box 724, SE-220 07 Lund
Tel: +46 46-19 20 00
Fax: +46 46-19 20 50

Copyright © Hugin ASA 2006. All rights reserved.

Contact Information